Drug news
Ipsen returns ROW rights to fipamezole to Santhera Pharma
Ipsen returns ROW rights to the adrenergic alpha-2 receptor antagonist fipamezole outside North America and Japan. Biovail ( now Valeant Pharma) returned the North American rights in 2010. Fipamezole is a first-in-class compound development for the treatment of levodopa-induced dyskinesia in Parkinson's disease and has completed Phase II trials. Santhera will seek other partners.